Skip to content
Subscriber Only

House Votes to Reauthorize and Expand FDA User Fees

The House passed a measure that would reauthorize drug and medical-device user-fee programs for five years and establish new user fees for the Food and Drug Administration’s review of generic drugs and biosimilar products.

“This bill is good for the FDA, it’s good for industry, and it’s good for patients alike,” said Frank Pallone, a Democrat whose district includes the New Brunswick, New Jersey headquarters of Johnson & Johnson.